Lantheus Holdings, Inc. (LNTH)
| Market Cap | 3.90B |
| Revenue (ttm) | 1.52B |
| Net Income (ttm) | 271.00M |
| Shares Out | 67.99M |
| EPS (ttm) | 3.77 |
| PE Ratio | 15.20 |
| Forward PE | 11.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,079,644 |
| Open | 58.06 |
| Previous Close | 58.13 |
| Day's Range | 56.27 - 58.13 |
| 52-Week Range | 47.25 - 118.21 |
| Beta | 0.09 |
| Analysts | Buy |
| Price Target | 74.50 (+29.94%) |
| Earnings Date | Nov 6, 2025 |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o... [Read more]
Financial Performance
In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for LNTH stock is "Buy." The 12-month stock price target is $74.5, which is an increase of 29.94% from the latest price.
News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquire...
LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) DEADLINE ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)? Did you purchase your shares between February 26, 2025 and...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquire...
Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, No...
LANTHEUS DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Lantheus Holdings Investors to Contact the Firm Before the November 10th Deadline
The lawsuit alleges Lantheus misled investors about Pylarify's pricing and competition, hiding risks that hurt its growth, revenue, and market position.
Lantheus Holdings: Not An Easy Buy, But The Company Continues To Create Value
Lantheus has seen a 50% stock decline due to weak results, reduced guidance and increased competition, but management is taking corrective actions. Q2 2025 results disappointed, with revenue and margi...
LNTH INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquire...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit - LNTH
NEW YORK , Oct. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH during the c...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Lawsuit - LNTH
NEW YORK , Sept. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH).
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for G...
Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) ...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options
Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information
SAN DIEGO , Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc....
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lantheus Holdings, Inc. (LNTH)
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of ...
LNTH LAWSUIT: Lantheus Holdings Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses
Block & Leviton announces that a securities fraud lawsuit has been filed against Lantheus Holdings Inc. (Nasdaq: LNTH). Investors should contactthe firm.
Lantheus Holdings, Inc. (LNTH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Robert Marshall - CFO & Treasurer Brian Markison - CEO...
LNTH Investors Have Opportunity to Join Lantheus Holdings, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Sept. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lantheus Holdings, I...
Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Brian A. Markison - CEO & Director Mark Richard Kinarney - Vice President of Inve...
Lantheus Holdings: Reassessing The Buy Thesis
Lantheus remains a highly profitable company with a dominant market share, an exceptionally strong balance sheet with nearly $1 billion in cash, and robust free cash flow. The stock's decline was driv...
Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resilience PDUFA date set for March 6, 2026
Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisitio...
Lantheus Holdings: Forget The Short Term Noise
Lantheus remains fundamentally strong despite recent stock drops, with long-term prospects intact for PYLARIFY and Alzheimer's diagnostics. PYLARIFY dominates revenue and has a significant growth runw...
Why Is Lantheus Stock Trading Lower On Wednesday?
Lantheus Holdings LNTH shares fell Wednesday after U.S. health agencies proposed changes to Medicare payment rules for hospital outpatient services and surgical centers starting in 2026.
Lantheus Seems Worth The (Very Real) Risks
Lantheus Holdings offers a compelling bull case with PYLARIFY and DEFINITY driving valuation and strong growth prospects. A headline multiple of 12x 2025 earnings obscures real risks around PYLARIFY r...